Reappraising the use of β-lactams to treat tuberculosis

Sebastian G. Kurz, Robert A. Bonomo

Research output: Contribution to journalReview articlepeer-review

27 Scopus citations

Abstract

The emergence of multidrug-resistant and extensively drug-resistant tuberculosis calls for novel approaches to treatment. Recent studies have shown that BlaC, the β-lactamase of Mycobacterium tuberculosis, is the major determinant of β-lactam resistance. This review invites the reader to explore evidence in order to answer the questions: can β-lactam and β-lactamase inhibitors adequately treat M. tuberculosis infection and are they a viable option in the management of resistant tuberculosis today?

Original languageEnglish
Pages (from-to)999-1006
Number of pages8
JournalExpert Review of Anti-Infective Therapy
Volume10
Issue number9
DOIs
StatePublished - Sep 2012
Externally publishedYes

Keywords

  • Mycobacterium tuberculosis
  • ampicillin/clavulanate
  • clavulanic acid
  • l,d transpeptidases
  • penicillin-binding protein
  • β-lactam
  • β-lactamase

Fingerprint

Dive into the research topics of 'Reappraising the use of β-lactams to treat tuberculosis'. Together they form a unique fingerprint.

Cite this